Search - tctmd.com

Displaying 41 - 60 of 837

Sort: Relevancy | Date

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Presentation ACC 2025

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Presenter: Darren K. McGuire

March 29, 2025

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

News Daily News

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Michael O'Riordan

March 26, 2025

AHA Offers Help for Clinicians Weighing the Results of DTC Genetic Tests

News Daily News

AHA Offers Help for Clinicians Weighing the Results of DTC Genetic Tests

Yael L. Maxwell

March 18, 2025

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

News Daily News

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

Michael O'Riordan

March 06, 2025

Can’t Exercise for a Cardiac Stress Test? That’s a Bad Sign

News Daily News

Can’t Exercise for a Cardiac Stress Test? That’s a Bad Sign

February 25, 2025

Invasive Testing Safely Diagnoses Microvascular Dysfunction in ANOCA

News Daily News

Invasive Testing Safely Diagnoses Microvascular Dysfunction in ANOCA

Michael O'Riordan

February 24, 2025

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

Use of Secondary CVD Prevention Meds Still Meager Worldwide

News Daily News

Use of Secondary CVD Prevention Meds Still Meager Worldwide

February 03, 2025

January 2025 Dispatch for the CV Team

News Opinion CV Team Dispatch

January 2025 Dispatch for the CV Team

January 24, 2025

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

Athletes’ Hearts Also Require Careful Scrutiny, New Review Suggests

News Daily News

Athletes’ Hearts Also Require Careful Scrutiny, New Review Suggests

Yael L. Maxwell

January 17, 2025

Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments

News Daily News

Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments

Michael O'Riordan

January 03, 2025

Top Coronary Artery Disease News in 2024

News Daily News

Top Coronary Artery Disease News in 2024

Michael O'Riordan

December 26, 2024

Sudden Cardiac Death in Athletes Is Rare, but Affects Black Population More

News Daily News

Sudden Cardiac Death in Athletes Is Rare, but Affects Black Population More

Michael O'Riordan

December 06, 2024

Questions Raised Anew About Aspirin for Secondary Prevention of ASCVD

News Daily News

Questions Raised Anew About Aspirin for Secondary Prevention of ASCVD

December 06, 2024

CVD Risks Vary by Type of Menopausal Hormone Replacement Therapy

News Daily News

CVD Risks Vary by Type of Menopausal Hormone Replacement Therapy

December 04, 2024

CMS Proposal Would Expand Medicare, Medicaid Coverage for GLP-1 Drugs

News Daily News

CMS Proposal Would Expand Medicare, Medicaid Coverage for GLP-1 Drugs

November 27, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.